Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Madecassoside Tablets Combined With Standard Therapy for Sclerotic Chronic Graft-versus-Host Disease
NCT07606703Phase 2Recruiting
- Sponsor
- WeiShi Biological
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of madecassoside in chronic graft-versus-host disease (cGVHD), sponsored by WeiShi Biological. Started Sep 2025; status: recruiting.
02
Drugs
madecassoside
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07606703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606703.